SEC Form 4 · accession 0001209191-18-010478
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pavan Cheruvu
Officer — Chief Executive Officer
Period of report
Feb 13, 2018
Accepted (ET)
Feb 15, 2018 · 5:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $1.81 | Feb 13, 2018 | A | 1,940,185 | A | — | Feb 12, 2028 | Common Shares | 1,940,185 | 1,940,185 | D |
Explanation of responses
- F125% of the common shares underlying the option will vest on February 11, 2019; the remainder vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.